tiprankstipranks
Trending News
More News >
Optimi Health Corp. (TSE:OPTI)
:OPTI
Advertisement

Optimi Health (OPTI) AI Stock Analysis

Compare
38 Followers

Top Page

TSE:OPTI

Optimi Health

(OPTI)

Rating:51Neutral
Price Target:
C$0.00
▼(-100.00%Downside)
The overall stock score for Optimi Health is driven primarily by its positive corporate events, which indicate strong future potential in the psychedelic-assisted therapy market. However, financial performance and valuation concerns, including persistent losses and negative cash flows, weigh down the score. Technical analysis also suggests a bearish trend, adding to the cautious outlook.

Optimi Health (OPTI) vs. iShares MSCI Canada ETF (EWC)

Optimi Health Business Overview & Revenue Model

Company DescriptionOptimi Health (OPTI) is a company focused on the development and production of natural health products and psychedelic compounds. Operating within the health and wellness sector, Optimi Health is committed to advancing mental health solutions through the cultivation and commercialization of functional mushrooms and psychedelic substances. The company emphasizes quality, safety, and efficacy in its products, aiming to provide innovative solutions for mental health challenges.
How the Company Makes MoneyOptimi Health generates revenue primarily through the cultivation and sale of functional mushrooms and psychedelic compounds. The company monetizes its operations via the production and distribution of health supplements derived from mushrooms, targeting both consumers and various health industries. Additionally, Optimi Health may engage in partnerships with research institutions and healthcare providers to develop psychedelic-assisted therapies, thereby creating potential revenue streams through collaborative agreements and licensing deals. The company's earnings are influenced by market demand for natural health products and the evolving regulatory landscape surrounding psychedelic substances.

Optimi Health Financial Statement Overview

Summary
Optimi Health exhibits revenue growth and sturdy equity levels, indicating potential for future profitability. However, persistent losses, negative cash flows, and reliance on external funding pose considerable financial risks. The company must focus on improving operational efficiency and cash management to enhance financial health.
Income Statement
45
Neutral
Optimi Health's revenue has shown growth from $0 in 2020 to $389,850 in 2024, indicating an upward trend. However, the company has consistently reported negative net income, with a significant net loss of $6,035,859 in 2024. The gross profit margin for 2024 is relatively healthy at 69.5%, but the absence of EBIT and negative EBITDA highlight challenges in operational efficiency.
Balance Sheet
60
Neutral
The company maintains a high equity ratio, with stockholders’ equity consistently exceeding total liabilities, indicating financial stability. The debt-to-equity ratio is moderate at 0.29 in 2024, suggesting manageable leverage. However, the declining trend in total assets and stockholders' equity since 2021 should be monitored.
Cash Flow
40
Negative
Optimi Health's cash flow demonstrates a challenging picture with negative operating and free cash flows in all observed years, reflecting cash management issues. The operating cash flow to net income ratio is negative, underscoring cash flow inadequacy to cover net losses. Despite positive financing cash flows, reliance on external financing is evident.
BreakdownSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income Statement
Total Revenue389.85K181.09K80.72K0.000.00
Gross Profit270.91K-157.04K53.92K-47.12K-5.42K
EBITDA-4.74M-4.42M-7.03M-5.95M-161.14K
Net Income-6.04M-5.19M-7.38M-6.04M-169.22K
Balance Sheet
Total Assets14.55M16.49M16.82M23.46M6.17M
Cash, Cash Equivalents and Short-Term Investments103.66K1.34M1.89M12.43M4.47M
Total Debt2.75M1.71M157.58K250.84K156.32K
Total Liabilities4.98M3.28M797.66K2.40M882.66K
Stockholders Equity9.58M13.21M16.02M21.07M5.29M
Cash Flow
Free Cash Flow-4.43M-4.41M-11.73M-10.96M-898.27K
Operating Cash Flow-4.28M-3.60M-4.58M-6.02M-143.45K
Investing Cash Flow-154.02K-706.02K-3.15M-9.19M-754.83K
Financing Cash Flow3.19M3.76M1.19M19.18M5.37M

Optimi Health Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.16
Price Trends
50DMA
0.17
Negative
100DMA
0.18
Negative
200DMA
0.20
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
49.55
Neutral
STOCH
57.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OPTI, the sentiment is Neutral. The current price of 0.16 is above the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.17, and below the 200-day MA of 0.20, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.55 is Neutral, neither overbought nor oversold. The STOCH value of 57.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:OPTI.

Optimi Health Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
C$23.14M20.084.53%4.09%
60
Neutral
HK$16.84B5.17-7.44%2.89%11.55%-28.15%
56
Neutral
$29.22M-2.68%29.78%68.83%
51
Neutral
C$15.46M-48.35%89.28%18.45%
46
Neutral
$19.83M-78.03%-11.84%20.29%
44
Neutral
$40.72M-76.00%66.13%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:OPTI
Optimi Health
0.16
-0.16
-50.00%
TSE:CWEB
Charlotte's Web Holdings
0.13
-0.11
-47.92%
TSE:ROMJ
Rubicon Organics
0.44
0.03
8.75%
TSE:NLH
Nova Leap Health
0.26
-0.03
-10.34%
TSE:PHRM
PharmaTher Holdings Ltd
0.46
0.22
91.67%

Optimi Health Corporate Events

Private Placements and Financing
Optimi Health Secures $3.45 Million Financing and Extends Loan
Neutral
Jul 18, 2025

Optimi Health Corp. has announced a $3.45 million convertible financing through a non-brokered private placement with two investors, which includes the company’s CEO and Chair of the Board. The funds will be used for general working capital, and the offering is expected to close by July 24, 2025. Additionally, Optimi has extended its secured term loan of $1 million, with a new maturity date set for April 30, 2026. This extension includes the issuance of 400,000 common share purchase warrants as partial consideration for the loan extension.

Product-Related AnnouncementsBusiness Operations and Strategy
Optimi Health Completes Major MDMA Export to Australia for PTSD Treatment
Positive
May 8, 2025

Optimi Health has completed its largest export of MDMA capsules to Australia, aimed at treating PTSD under the country’s Authorised Prescriber Scheme. This shipment, in partnership with Mind Medicine Australia, includes 1,000 GMP-certified MDMA capsules and marks a significant development as the Australian Department of Veterans’ Affairs will fund MDMA-assisted therapy for veterans. This initiative reflects growing governmental recognition of psychedelic-assisted treatments for mental health, potentially enhancing Optimi’s industry positioning and expanding access to innovative therapies.

Product-Related AnnouncementsRegulatory Filings and Compliance
Optimi Health Secures U.S. FDA Registration for Psychedelic Drug Supply
Positive
May 5, 2025

Optimi Health Corp. has obtained U.S. FDA Drug Establishment Registration, marking a significant regulatory milestone that allows the company to supply GMP-certified MDMA and psilocybin to authorized entities in the United States. This recognition positions Optimi to participate in the U.S. pharmaceutical supply chain, a crucial step as the U.S. market represents a significant opportunity for psychedelic-assisted therapies. The registration enables Optimi to engage in FDA filings, supply U.S. distributors, and file Abbreviated New Drug Applications (ANDAs) for generic formulations, enhancing its industry positioning and potential impact on stakeholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 10, 2025